SHARx Analyzes TrumpRx: Transparency on Drug Costs Doesn’t Resolve Pricing and Access Gatekeeping

The launch of the TrumpRx platform has put prescription drug pricing back in the spotlight, but lower list prices are only half the battle. The true gatekeepers of affordability and access remain the Pharmacy Benefit Managers (PBMs), whose opaque rebate structures and vertical integration create a “multi-layered obstacle course” for patients and employers alike.

Real reform requires more than just headline-grabbing price cuts; it demands a dismantling of the “black box” incentives that control coverage and distribution, especially in the high-stakes world of specialty drugs. Without addressing the systemic complexity of the PBM maze, the benefits of lower pricing may never actually reach the patients they intend to help.